Case Series {#Sec1}
===========

In everyday clinical practice, patients frequently present with bilateral diabetic macular edema (DME), yet there is a paucity of reported data on the bilateral use of DME therapies \[[@CR1]\]. ILUVIEN^®^ \[fluocinolone acetonide (FAc) implant\] is indicated for the treatment of vision impairment associated with chronic DME, considered insufficiently responsive to available therapies \[[@CR2]\]. A single implant in the affected eye is recommended, with the fellow eye being available for therapy but not at the same time or visit as the first eye \[[@CR2]\]. This inevitably means that treatment of the fellow eye is delayed; however, early intervention is important in the management of DME as prolonged edema can lead to irreversible damage and permanent vision loss \[[@CR3]\].

The structural and functional responses following bilateral intravitreal injections of the FAc implant have been reported previously \[[@CR4]\]. The objective of this case series is to report the structural and functional responses 12 months after intravitreal injection of the FAc implant.

Data are presented from 10 eyes. The demographics for the group and prior therapies are presented in Table [1](#Tab1){ref-type="table"}. Prior to intravitreal injection of the FAc implant, all patients had received at least one macular laser therapy for DME. Patients had also received an average of 8.9 (range 3--19) intravitreal injections of an anti-VEGF and 1.2 (range 0--3) intravitreal injections of triamcinolone acetonide. This article does not contain any new studies with human or animal subjects performed by any of the authors.Table 1Patient demographics and baseline valuesPatient numberGenderAgeDiabetes typeEye numberLeft or right eyeIOP-lowering dropsPrior medical treatment for DMEDate of 0.2 μ/g day FAc implantLaserRBZIVTA1Male70II1LEN1× Grid9×1×July 29, 20142REN1× Grid9×1×September 9, 20142Female58II3RELumigan/azarga1× Focal19×1×June 10, 20144LELumigan/azarga2× Focal19×1×September 23, 20143Male44I5RELatanoprost/timolol1× Grid6×3×July 25, 20146LELatanoprost/timolol1× Grid6×2×October 30, 20144Male82II7REN1× Grid3×2×April 10, 20148LEN1× Grid3×1×July 11, 20145Male63I9LEN1× Grid6×0July 18, 201410REN1× Grid9×0October 21, 2014*DME* diabetic macular edema, *FAc* fluocinolone acetonide, *IOP* intraocular pressure, *IVTA* intravitreal triamcinolone, *LE* left eye, *RE* right eye, *RBZ* ranibizumab

Figure [1](#Fig1){ref-type="fig"} plots central retinal thickness (CRT) for each patient and Table [2](#Tab2){ref-type="table"} shows the mean changes from baseline. There was a decrease in CRT for 9 of the 10 patients at month 6 or month 12. A single patient (patient 9) initially showed a small (+16 microns) increase in CRT at 6 months but a much greater reduction (−182 microns) at 12 months indicating a delayed response, whereas for patient 10 the changes at months 6 and 12 were comparatively smaller (−22 microns at month 6 and +2 microns at months 12). Overall, mean CRT decreased by −303.6 ± 238.7 microns (−42.1 ± 31.5%) and −357.9 ± 200.3 microns (−50.9 ± 24.2%) at 6 and 12 months, respectively, from a baseline of 645.3 ± 176.1 microns.Fig. 1Individual patient (eyes*1*--*10*) plots of central retinal thickness (microns) at baseline (*black line*) and 6 months (*blue line*) and 12 months (*red line*) after intravitreal injection of the fluocinolone acetonide implantTable 2Mean visual acuity, central retinal thickness and intraocular pressure at baseline and 6 and 12 months after intravitreal injection of the fluocinolone acetonide implantMeasureBaseline6 months12 monthsVisual acuity, ETDRS letters44.5 ± 18.6+11.0 ± 13.1+10.5 ± 13.0Central retinal thickness, µm645.3 ± 176.1−303.6 ± 238.7−357.9 ± 200.3Intraocular pressure, mmHg13.7 ± 3.6+1.8 ± 4.5+2.3 ± 4.0Data are presented as mean ± standard deviation*ETDRS* Early Treatment Diabetic Retinopathy Study

Figure [2](#Fig2){ref-type="fig"} plots visual acuity (VA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters for each patient and Table [2](#Tab2){ref-type="table"} shows the mean changes from baseline. At 6 and 12 months, VA was sustained or improved in 9 out of 10 patients with letter gains from baseline ranging between 0 and 35 ETDRS letters. Overall, mean VA increased by 11.0 ± 13.1 and 10.5 ± 13.0 ETDRS letters after 6 and 12 months, respectively, from a baseline of 44.5 ± 18.6 ETDRS letters.Fig. 2Visual acuity in Early Treatment Diabetic Retinopathy Study ETDRS letters for each patient (numbered*1*--*10*) at baseline (*black line*), 6 months (*blue line*) and 12 months (*red line*) after intravitreal injection of the fluocinolone acetonide implant

Intraocular pressure (IOP) was also measured at baseline (mean of 13.7 ± 3.6 mmHg), 6 months (mean 15.5 ± 4.0 mmHg) and 12 months (mean 16.0 ± 3.3 mmHg). Table [2](#Tab2){ref-type="table"} shows the mean changes from baseline. In all cases, IOP remained ≤21 mmHg.

Conclusion {#Sec2}
==========

The patients followed up in our bilateral case series show clinical improvement up to 12 months after intravitreal FAc implantation. Over 12 months, nine out of ten patients had sustained and improved VA with mean improvements of 10.5 letters, and a mean reduction of −357.9 microns in CRT from baseline with no patients experiencing a rise of IOP above 21 mmHg.
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